BEP Targeting Strategies in Ethiopia (BEP)
Targeting Strategies of Antenatal Balanced Energy and Protein Supplementation in Addis Ababa, Ethiopia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Wafaie W Fawzi, DrPH, MBBS
- Phone Number: 617-432-7598
- Email: mina@hsph.harvard.edu
Study Locations
-
-
Addis Ababa
-
Addis Ababa, Addis Ababa, Ethiopia, Box 26751/1000
- Addis Continental Institute of Public Health (ACIPH)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- pregnant women aged 18 to 49;
- attending antenatal visits in one of the study health facilities;
- with a gestational age of 24 weeks or less;
- no known allergies to peanuts or soybeans;
- having resided in the current location for at least 6 months;
- intending to continue antenatal follow-up in the health facility;
- intending to give birth and remain in the study area until six weeks after delivery; and
- willing to take the BEP supplements for the entire duration of the pregnancy if eligible.
Exclusion Criteria:
- Not meeting all of the inclusion criteria above
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Arm 1 (control arm)
In Arm 1 (control arm), participants will receive the standard of antenatal care including iron and folic acid supplementation.
|
|
|
Experimental: Arm 2 (Targeted BEP based on baseline nutritional status)
|
In Arm 2 (targeted BEP based on baseline nutritional status), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm.
|
|
Experimental: Arm 3 (Targeted BEP by baseline nutritional status and monthly gestational weight gain monitoring)
|
In Arm 3 (targeted BEP based on baseline nutritional status and monthly GWG monitoring), in addition to the standard of care, participants will receive BEP supplements if their baseline BMI is less than 18.5 or their baseline mid-upper arm circumference is less than 23 cm; participants with an inadequate GWG at a monthly follow-up visit will receive additional BEP supplements.
|
|
Experimental: Arm 4 (universal BEP)
|
In Arm 4 (universal BEP), all participants will receive BEP supplements from baseline through the end of pregnancy.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Small-for-gestational-age births
Time Frame: Assessed within 72 hours of birth
|
Live birth whose birthweight for sex and gestational age is < 10th percentile based on the INTERGROWTH-21st standards
|
Assessed within 72 hours of birth
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Inadequate gestational weight gain
Time Frame: At the last weight measurement before delivery, at around 36 weeks
|
Gestational weight gain percent adequacy ratio less than 90% at the last weight measurement before delivery, based on the Institute of Medicine recommendations
|
At the last weight measurement before delivery, at around 36 weeks
|
|
Excessive gestational weight gain
Time Frame: At the last weight measurement before delivery, at around 36 weeks
|
Gestational weight gain percent adequacy ratio greater than 125% at the last weight measurement before delivery, based on the Institute of Medicine recommendations
|
At the last weight measurement before delivery, at around 36 weeks
|
|
Stillbirth
Time Frame: Between 28 weeks of gestation and delivery
|
Fetal death between 28 weeks of gestation and delivery
|
Between 28 weeks of gestation and delivery
|
|
Preterm birth
Time Frame: Less than 37 completed weeks of gestation
|
Live birth < 37 completed weeks of gestation
|
Less than 37 completed weeks of gestation
|
|
Low birthweight
Time Frame: Assessed within 72 hours of birth
|
Live birth weighing < 2500 grams
|
Assessed within 72 hours of birth
|
|
Macrosomia
Time Frame: Assessed within 72 hours of birth
|
Live birth weighing > 4000 grams
|
Assessed within 72 hours of birth
|
|
Large-for-gestational-age births
Time Frame: Assessed within 72 hours of birth
|
Live birth whose birthweight for sex and gestational age is > 90th percentile based on the INTERGROWTH-21st standards
|
Assessed within 72 hours of birth
|
|
Third-trimester anemia
Time Frame: At 32 weeks of gestation
|
Hemoglobin concentration < 11 g/dL at 32 weeks of gestation
|
At 32 weeks of gestation
|
|
Neonatal death
Time Frame: From birth through 28 days of life
|
Death of live newborn < 28 days of life
|
From birth through 28 days of life
|
|
Perinatal death
Time Frame: Between 28 weeks of gestation to 7 days after delivery
|
Fetal death between 28 weeks gestational age and delivery, or newborn death < 7 days of life
|
Between 28 weeks of gestation to 7 days after delivery
|
|
Pre-eclampsia
Time Frame: After 20 weeks of gestation
|
New onset hypertension (systolic blood pressure >= 140 or diastolic blood pressure >=90 mmhg) after 20 weeks of gestation with proteinuria.
|
After 20 weeks of gestation
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Wafaie W Fawzi, DrPH, MBBS, Harvard School of Public Health (HSPH)
- Principal Investigator: Yemane Berhane, MD, PhD, Addis Continental Institute of Public Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Female Urogenital Diseases and Pregnancy Complications
- Body Weight
- Obstetric Labor, Premature
- Obstetric Labor Complications
- Pregnancy Complications
- Body Weight Changes
- Death
- Fetal Death
- Weight Gain
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Gestational Weight Gain
- Premature Birth
- Birth Weight
- Stillbirth
- Perinatal Death
Other Study ID Numbers
Other Study ID Numbers
- IRB22-1245
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.